PEPFAR's annual planning process is done either at the country (COP) or regional level (ROP).
PEPFAR's programs are implemented through implementing partners who apply for funding based on PEPFAR's published Requests for Applications.
Since 2010, PEPFAR COPs have grouped implementing partners according to an organizational type. We have retroactively applied these classifications to earlier years in the database as well.
Also called "Strategic Areas", these are general areas of HIV programming. Each program area has several corresponding budget codes.
Specific areas of HIV programming. Budget Codes are the lowest level of spending data available.
Expenditure Program Areas track general areas of PEPFAR expenditure.
Subdivisions of Program Areas, these track general higher level sub-classifications of expenditure.
Subdivisions of Major categories, these are the most detailed expenditure data.
Cross-cutting attributions are areas of PEPFAR programming that contribute across several program areas. They contain limited indicative information related to aspects such as human resources, health infrastructure, or key populations programming. However, they represent only a small proportion of the total funds that PEPFAR allocates through the COP process. Additionally, they have changed significantly over the years. As such, analysis and interpretation of these data should be approached carefully. Learn more
PEPFAR sets targets using the Monitoring, Evaluation, and Reporting (MER) System - documentation for which can be found on PEPFAR's website at https://www.pepfar.gov/reports/guidance/. As with most data on this website, the targets here have been extracted from the COP documents. Targets are for the fiscal year following each COP year, such that selecting 2016 will access targets for FY2017. This feature is currently experimental and should be used for exploratory purposes only at present.
Years of mechanism: 2008
The EP relies heavily upon pharmaceutical interventions for the success of the overall program. However,
these drugs often have secondary adverse effects that diminish their primary therapeutic benefits. While
the antiretroviral and anti-infective drugs employed by the EP are well characterized, many could have
adverse effects that remain unrecognized in certain clinical circumstances.
In FY 2007, the overall goal of this activity was to provide a simple, small-scale program of passive
surveillance for adverse events among Rwandan patients who receive EP-distributed pharmaceuticals. This
activity was programmed to receive support from the FDA. However, because of the preliminary work done
by RPM+ with the Rwandan national drug task force and the need to conduct this activity through regional
collaboration based on experiences in other African countries, the funds were reprogrammed to RPM+.
RPM+ in collaboration with PMI, TRAC and APHAR provided TA to establish a small-scale program of
passive surveillance for adverse events. This is the first categorical drug safety program instituted in
Rwanda. RPM+ trained caregivers in select hospitals in the use of simplified reporting forms, and trained a
GOR-based analyst in their appropriate interpretation. In addition, RPM+ has provided periodic QA and
supervision to those health care providers to ensure appropriate completion of the reports, quality of data,
and reporting to the NDA and PTF.
In FY 2008, EP will build on this innovative activity by assisting the Pharmaceutical Task Force to establish
a pharmacovigilance system at the central and district levels. In FY 2008, SPS (the new follow-on
mechanism to RPM+), will conduct training for health providers, implement data collection, reporting,
assessing, communicating and monitoring on drug cohort in sentinel sites, scale up data collection and drug
cohort monitoring to all facilities, build capacity of the NDA and PTF to analyze and validate
pharmacovigilance data and evaluate the pharmacovigilance system.
This activity will complement PMI investments to ensure that pharmacovigilance systems strengthening is
integrated across HIV/AIDS and Malaria drugs. This activity reflects the ideas presented in the Rwanda EP
five-year strategy and the National Prevention Plan by providing quality assurance of treatment
commodities, and strengthening the quality of ARV services.
In FY 2007, the EP scaled up its technical and management support to the NDA. RPM-Plus helped develop
an implementation plan that defined the roles and responsibilities of a pharmaceutical regulatory authority.
RPM-Plus also supported a strategic plan that established a drug registration system; created national QA
in drug testing, inspection, and monitoring; and supported policies and procedures for drug regulation. The
EP built the capacity of pharmacists by providing materials, training pharmacists, and supporting the
University of Butare's School of Pharmacy to integrate HIV/AIDS pharmaceutical management into its pre-
service curriculum. Additionally, RPM-Plus developed a fee structure for commercial registration of drugs,
including pricing policy and plans for financial audits. Strengthening Pharmaceutical Systems (SPS) is the
RPM-Plus follow-on in FY 2008. SPS will continue to support the NDA in FY 2008 primarily in drug
registration, testing QA, inspection and monitoring, and policies for drug regulation. SPS will also provide
support in developing pricing policies and procedures for health providers.
In addition to the NDA support in FY 2007, RPM-Plus also provided managerial and technical assistance to
the Pharmaceutical Task Force (PTF). RPM-Plus ensured that the PTF met the requirements to
decentralize pharmaceutical management to districts and provided TA to establish and make the national
drug registration system operational. SPS will continue these activities in FY 2008, as well as assist PTF in
the development and implementation of the National Pharmaceutical Pricing Policy. Furthermore, the EP
will support the strengthening of systems and institutional capacity of the PTF to ensure effective
decentralization and integration of pharmaceutical functions and activities.
In FY 2007, RPM-Plus began to promote rational drug use in the public and private sector. In collaboration
with the Rwanda Medical Board and PTF, RPM-Plus consolidated Drugs and Therapeutics Committees
(DTC) activities in eight hospitals and expanded to 10 others. In FY 2008, SPS will expand DTC activities to
22 new hospitals. In FY 2008, the EP will also continue to build and strengthen systems and institutional
capacity of the PTF and ARPHA to reinforce the implementation of the national pharmaceutical policy and
organize forums on rational drug use in the private sector. SPS will also build the capacity of RAMA in
pharmaceutical management, rational drug use and implementation of national pharmaceutical policy. In
collaboration with the National University of Rwanda (NUR), SPS will facilitate the integration of the
pharmaceutical management in the academic curriculum and assist NUR in operational research on rational
This activity reflects the Rwanda EP five-year strategy and supports the GOR's national strategy of human
resources and organizational capacity building.